Meeting Abstract
ASH Highlights and Commentary: Multiple Myeloma
J Adv Pract Oncol 2021;12(suppl 3):4-10 |
https://doi.org/10.6004/jadpro.2021.12.3.28 |
© 2021 Harborside™
ABSTRACT
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2020 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitioner.
Dr. Faiman considers the use of qualitative interviews to understand the patient perspective on the clinical benefits and tolerability of belamaf. She also highlights the safety profile and noninferiority of subcutaneous daratumumab compared with IV daratumumab, as described in the APOLLO trial. Finally, Dr. Faiman emphasizes the importance of achieving MRD negativity measured by multiparameter flow cytometry and next-generation sequencing.
On the JADPRO website, you’ll find several short videos on these important abstracts that the faculty members filmed on site. Visit advancedpractitioner.com/highlights to continue the experience!
For access to the full length article, please
sign in.
